

PEOPLE

Spring Bank Pharmaceuticals (Milford, MA, USA) has appointed **Nezam Afdhal** chief medical officer. Afdhal will remain as a senior physician at the Liver Center at Beth Israel Deaconess Medical Center and professor of medicine at Harvard Medical School. He has been a consultant to Spring Bank since 2011 and has served as the company's non-executive chief medical officer since 2015.

EPIRUS Biopharmaceuticals (Boston) has announced the appointment of **Vincent E. Aurentz** as chief business officer. Aurentz most recently served as the president of HemoShear Therapeutics and was previously executive vice president and a member of the executive management board at Merck KGaA (Merck Serono).

Robert Azelby has been named executive vice president and chief commercial officer at Juno Therapeutics (Seattle). He previously served as head of Amgen's oncology business unit.

Kurt Graves has been appointed to the board of directors of Seres Therapeutics (Cambridge, MA, USA). He currently serves as chairman, president and CEO of Intarcia Therapeutics.

Peter Greenleaf has been named as a director of Mast Therapeutics (San Diego). He currently serves as CEO and a member of the board of directors of Sucampo Pharmaceuticals. Before joining Sucampo, he was CEO and a member of the board of directors of Histogenics.



Richard Hague (left) has been appointed chief commercial officer of Anika Therapeutics (Bedford, MA, USA). He has over three decades of commercial leadership experience in the

sciences sector, most recently serving as vice president, sales and marketing for TEI Medical. Previously, he was vice president sales, marketing and commercial operations at Sanofi Biosurgery.

AVEO Oncology (Cambridge, MA, USA) has announced that **Tuan Ha-Ngoc** has stepped

down as chairman and a director of the company's board of directors after 13 years of service to pursue outside interests. **Henri A. Termeer**, lead outside director and former chairman, CEO and president of Genzyme, has assumed leadership responsibilities for the AVEO board.

NeuroVive Pharmaceutical (Lund, Sweden) has announced the appointment of **Magnus Hansson** as chief medical officer, effective 1 January 2016. Hansson had previously served as a part-time clinical scientist at NeuroVive. In addition, he is a consultant physician and associate professor in medical imaging and physiology at Skåne University Hospital.

Human Longevity (San Diego) has named **Sally Howard** as head of regulatory affairs and policy. She joins the company with two decades of health policy and regulatory expertise, most recently at the US Food and Drug Administration where she was senior advisor and acting chief of staff to the FDA Commissioner. She was previously FDA Deputy Commissioner for Policy, Planning and Legislation, during which time she directed the team implementing the White House's Precision Medicine Initiative.



Monoclonal antibody therapeutics developer Arsanis (Boston and Vienna) has announced the appointment of **David Mantus** (left) as executive vice president, regulatory affairs, clinical and

technical operations. Mantus joins the company from BIND Therapeutics, where he served as vice president, regulatory affairs and quality assurance. Prior to BIND, he was vice president of regulatory affairs at Cubist Pharmaceuticals.

Privately held Wilson Therapeutics (Stockholm) has named **Anders Martin-Lof** as CFO. Martin-Lof has more than 15 years' experience in the life science sector, most recently serving as CFO of Extenda and RaySearch Laboratories.

Paul Michalet has been named chairman of the management board of iDD biotech (Lyon, France). He was most recently CFO of industrial biotech company Fermentalg.

Ocular Therapeutix (Bedford, MA, USA) has announced that **W. James O'Shea** has been elected to the company's board of directors. O'Shea is the former president and COO of Sepracor.

Cardica (Redwood City, CA, USA) has announced the appointment of **Thomas J. Palermo** as COO. He was most recently acting CEO of UlceRx Medical and previously president and CEO of ReVascular Therapeutics.

Vaccine developer ImevaX (Munich) has announced the appointment of **Marie Roskrow** as CEO and **Staph Leavenworth Bakali** as chairman of the supervisory board. Roskrow was most recently CEO and managing director of Australian biotech company Patrys. She succeeds **Volker Wedershoven**, who had served as acting CEO since September 2014 and who will remain as the company's CFO. Leavenworth Bakali was previously president and CEO of Genocea Biosciences and COO of both PowderJect Pharmaceuticals and ID Biomedical.

Antibacterial therapy developer AmpliPhi Biosciences (Richmond, VA, USA) has announced the appointments of **Vijay B. Samant** and **Paul C. Grint** to its board of directors. Samant is president and CEO of Vical and was previously CEO of the Merck's vaccine division, vice president of vaccine operations, vice president of business affairs and executive director of materials management at Merck. Grint is president and CEO of Regulus Therapeutics and formerly president of Cerexa.

Privately held OticPharma (Irvine, CA, USA) has appointed **Catherine C. Turkel** to the position of senior vice president clinical research and development and chief development officer. She brings more than 30 years of combined clinical practice and drug development experience, most recently serving as vice president of clinical development for Allergan's neurology and pain franchise.